A New Cell Block Method for Multiple Immunohistochemical Analysis of Circulating Tumor Cells in Patients with Liver Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose We developed a new method of detecting circulating tumor cells (CTCs) in liver cancer patients by constructing cell blocks from peripheral blood cells, including CTCs, followed by multiple immunohistochemical analysis. Materials and Methods Cell blocks were constructed from the nucleated cell pellets of peripheral blood after removal of red blood cells. The blood cell blocks were obtained from 29 patients with liver cancer, and from healthy donor blood spiked with seven cell lines. The cell blocks and corresponding tumor tissues were immunostained with antibodies to seven markers: cytokeratin (CK), epithelial cell adhesion molecule (EpCAM), epithelial membrane antigen (EMA), CK18, -fetoprotein (AFP), Glypican 3, and HepPar1. Results The average recovery rate of spiked SW620 cells from blood cell blocks was 91%. CTCs were detected in 14 out of 29 patients (48.3%); 11/23 hepatocellular carcinomas (HCC), 1/2 cholangiocarcinomas (CC), 1/1 combined HCC-CC, and 1/3 metastatic cancers. CTCs from 14 patients were positive for EpCAM (57.1%), EMA (42.9%), AFP (21.4%), CK18 (14.3%), Gypican3 and CK (7.1%, each), and HepPar1 (0%). Patients with HCC expressed EpCAM, EMA, CK18, and AFP in tissue and/or CTCs, whereas CK, HepPar1, and Glypican3 were expressed only in tissue. Only EMA was significantly associated with the expressions in CTC and tissue. CTC detection was associated with higher T stage and portal vein invasion in HCC patients. Conclusion This cell block method allows cytologic detection and multiple immunohistochemical analysis of CTCs. Our results show that tissue biomarkers of HCC may not be useful for the detection of CTC. EpCAM could be a candidate marker for CTCs in patients with HCC.
Abstract
Purpose We developed a new method of detecting circulating tumor cells (CTCs) in liver cancer patients by constructing cell blocks from peripheral blood cells, including CTCs, followed by multiple immunohistochemical analysis. Materials and Methods Cell blocks were constructed from the nucleated cell pellets of peripheral blood after removal of red blood cells. The blood cell blocks were obtained from 29 patients with liver cancer, and from healthy donor blood spiked with seven cell lines. The cell blocks and corresponding tumor tissues were immunostained with antibodies to seven markers: cytokeratin (CK), epithelial cell adhesion molecule (EpCAM), epithelial membrane antigen (EMA), CK18, -fetoprotein (AFP), Glypican 3, and HepPar1. Results The average recovery rate of spiked SW620 cells from blood cell blocks was 91%. CTCs were detected in 14 out of 29 patients (48.3%); 11/23 hepatocellular carcinomas (HCC), 1/2 cholangiocarcinomas (CC), 1/1 combined HCC-CC, and 1/3 metastatic cancers. CTCs from 14 patients were positive for EpCAM (57.1%), EMA (42.9%), AFP (21.4%), CK18 (14.3%), Gypican3 and CK (7.1%, each), and HepPar1 (0%). Patients with HCC expressed EpCAM, EMA, CK18, and AFP in tissue and/or CTCs, whereas CK, HepPar1, and Glypican3 were expressed only in tissue. Only EMA was significantly associated with the expressions in CTC and tissue. CTC detection was associated with higher T stage and portal vein invasion in HCC patients. Conclusion This cell block method allows cytologic detection and multiple immunohistochemical analysis of CTCs. Our results show that tissue biomarkers of HCC may not be useful for the detection of CTC. EpCAM could be a candidate marker for CTCs in patients with HCC.
참고문헌 (29)
- Jemal A, "Global cancer statistics", CA Cancer J Clin, 61, pp.69~90 (2011)
- Park JW, "Global patterns of hepatocellular carcinoma management from diagnosis to death : the BRIDGE Study", Liver Int, 35, pp.2155~2166 (2015)
- Arnaoutakis DJ, "Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver : a multi-institutional analysis", Ann Surg Oncol, 21, pp.147~154 (2014)
- Sumie S, "The significance of classifying microvascular invasion in patients with hepatocellular carcinoma", Ann Surg Oncol, 21, pp.1002~1009 (2014)
- Harouaka R, "Circulating tumor cells : advances in isolation and analysis, and challenges for clinical applications", Pharmacol Ther, 141, pp.209~221 (2014)
- Hyun KA, "Microfluidic flow fractionation device for label-free isolation of circulating tumor cells(CTCs)from breast cancer patients", Biosens Bioelectron, 40, pp.206~212 (2013)
- Grover PK, "Circulating tumour cells : the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research", Ann Oncol, 25, pp.1506~1516 (2014)
- Patriarca C, "Epithelial cell adhesion molecule in cancer : a short review", Cancer Treat Rev, 38, pp.68~75 (2012)
- Nagrath S, "Isolation of rare circulating tumour cells in cancer patients by microchip technology", Nature, 450, pp.1235~1239 (2007)
- Went PT, "Frequent EpCam protein expression in human carcinomas", Hum Pathol, 35, pp.122~128 (2004)
- 박현진, "SALL4 Expression in Hepatocellular Carcinomas Is Associated with EpCAM-Positivity and a Poor Prognosis", Journal of Pathology and Translational Medicine, 49(5), pp.373~381 (2015), 대한병리학회[DOI]
- Hewitt RE, "Validation of a model of colon cancer progression", J Pathol, 192, pp.446~454 (2000)
- Bosman FT, "WHO classification of tumours of the digestive system" (2010), IARC Press
- Compton CC, "AJCC cancer staging atlas: a companion to the seventh editions of the AJCC cancer staging manual and handbook" (2012), Springer
- Vona G, "Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulatingtumor cells", Am J Pathol, 156, pp.57~63 (2000)
- Zieglschmid V, "Detection of disseminated tumor cells in peripheral blood", Crit Rev Clin Lab Sci, 42, pp.155~196 (2005)
- Rolle A, "Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC(R)is a predictor for relapse : a preliminary report", World J Surg Oncol, 3, pp.18~ (2005)
- Chiappini F, "Circulating tumor cells measurements in hepatocellular carcinoma", Int J Hepatol, 2012, pp.684802~ (2012)
- Xu W, "Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategy", Clin Cancer Res, 17, pp.3783~3793 (2011)
- Fan ST, "Prediction of posthepatectomy recurrence of hepatocellular carcinoma by circulating cancer stem cells : a prospective study", Ann Surg, 254, pp.569~576 (2011)
- Ignatiadis M, "Circulating tumor cells and circulating tumor DNA : challenges and opportunities on the path to clinical utility", Clin Cancer Res, 21, pp.4786~4800 (2015)
- Schulze K, "Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma", Int J Cancer, 133, pp.2165~2171 (2013)
- Sun YF, "Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection", Hepatology, 57, pp.1458~1468 (2013)
- Ruck P, "Ep-CAM in malignant liver tumours", J Pathol, 191, pp.102~103 (2000)
- de Boer CJ, "Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver", J Pathol, 188, pp.201~206 (1999)
- Yamashita T, "EpCAM-positive hepatocellular carcinoma cells are tumorinitiating cells with stem", progenitor cell features, 2009, pp.136, 1012~1024
- Terris B, "EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma", J Hepatol, 52, pp.280~281 (2010)
- Bednarz-Knoll N, "Plasticity of disseminating cancer cells in patients with epithelial malignancies", Cancer Metastasis Rev, 31, pp.673~687 (2012)
- Mani SA, "The epithelial-mesenchymal transition generates cells with properties of stem cells", Cell, 133, pp.704~715 (2008)